CRISPR/Cas9-based stem cell therapy（Novartis）

N/A

Report date: 2023/02/24 15:40:48

Base Information

Drug NameCRISPR/Cas9-based stem cell therapy（Novartis）
Drug Alias NameADPT-03
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionFetal hemoglobin agonistsStem cell replacements
TargetsFetal hemoglobin
Therapy Area/IndicationsAnemia, Sickle Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsAnemia, Sickle Cell

Other Information

ATC CodeN/A
Related LinksN/A